We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00760526
Recruitment Status : Completed
First Posted : September 26, 2008
Results First Posted : December 4, 2013
Last Update Posted : October 19, 2016
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Supportive Care
Condition: Diabetes Mellitus, Type 1
Interventions: Device: Continuous glucose monitor
Device: Home blood glucose monitor

  Participant Flow


  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Continuous Glucose Montoring Treatment group
Standard Glucose Monitoring With a Home Glucose Meter Control Group
Total Total of all reporting groups

Baseline Measures
   Continuous Glucose Montoring   Standard Glucose Monitoring With a Home Glucose Meter   Total 
Overall Participants Analyzed 
[Units: Participants]
 74   72   146 
Age 
[Units: Participants]
     
<=18 years   74   72   146 
Between 18 and 65 years   0   0   0 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 7.5  (1.8)   7.5  (1.7)   7.5  (1.7) 
Gender 
[Units: Participants]
     
Female   34   33   67 
Male   40   39   79 
Region of Enrollment 
[Units: Participants]
     
United States   74   72   146 


  Outcome Measures

1.  Primary:   Number of Participants With a Decrease >=0.5% HbA1c With no Severe Hypoglycemic Events   [ Time Frame: 26 weeks ]

2.  Secondary:   Number of Severe Hypoglycemic Events Experienced by Participants   [ Time Frame: 26 weeks ]

3.  Secondary:   CGM Glucose Values (mg/dL)   [ Time Frame: 26 weeks ]

4.  Secondary:   Biochemical Hypoglycemia (Percentage of Sensor Values </= 70 mg/dL)   [ Time Frame: 26 weeks ]

5.  Secondary:   Measures of Variability: Standard Deviation (SD)   [ Time Frame: 26 weeks ]

6.  Secondary:   Measures of Variability: Mean Absolute Rate of Change   [ Time Frame: 26 weeks ]

7.  Secondary:   Measures of Variability: Mean Amplitude of Glycemic Excursions (MAGE)   [ Time Frame: 26 weeks ]

8.  Secondary:   Parental Quality of Life Measures: Hypoglycemia Fear Survey   [ Time Frame: 26 weeks ]

9.  Secondary:   Parental Quality of Life Measures: PAID (Problem Areas in Diabetes)   [ Time Frame: 26 weeks ]

10.  Secondary:   Parental Quality of Life Measures: Blood Glucose Monitoring System Rating Scale   [ Time Frame: 26 weeks ]

11.  Secondary:   Parental Quality of Life Measures: CGM Satisfaction Scale   [ Time Frame: 26 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information